Rational Pharmacotherapy in Cardiology

Advanced search

Chronic Heart Failure in Rheumatoid Arthritis Patients (Part I): Prevalence, Etiology and Pathogenesis

Full Text:


Rheumatoid arthritis (RA) is a disease with a high cardiovascular risk, which is caused, in particular, by an increased incidence of chronic heart  failure (CHF). Analysis of the results of the main studies on the prevalence of CHF, the features of the etiology and pathogenesis of myocardial dysfunction in RA was the purpose of the review. According to the registers, population and epidemiological studies, the risk of CHF and CHF-associated mortality in RA patients is 1.5-2.5 times higher than in the general population. In most of the studies only clinically manifested congestive heart  failure (HF) was considered, so the actual prevalence of CHF may be significantly underestimated. An increase in the risk of CHF was noted immediately after the debut of RA, with the prevalence of HF with preserved systolic function of the left ventricle, which indicates the important role of diastole disturbance in the pathogenesis of myocardial dysfunction. Chronic systemic autoimmune inflammation contributes to the  development of CHF in RA patients, in addition to coronary heart disease, traditional risk factors (TRFs) of cardiovascular diseases (CVD). Inflammation plays a leading role in the development of CHF through various mechanisms including direct damage to the myocardium and coronary arteries (myocarditis, coronary vasculitis, microcirculatory disorders), aggravation of the severity of TRFs of CVD, accelerated progression of ischemic heart  disease, endothelial dysfunction, increased vascular wall stiffness, cardiac and vascular remodeling. Early diagnosis of CHF and timely measures that can slow its progression is needed due to the high risk of CHF and CHF-associated mortality in RA patients, especially in patients with risk factors for CHF.

About the Authors

D. S. Novikova
V.A. Nasonova Research Institute of Rheumatology
Russian Federation

Diana S. Novikova – MD, PhD, Leading Researcher, Rheumocardiology Laboratory.

Kashirskoe shosse 34a, Moscow, 115522.


I. G. Kirillova
V.A. Nasonova Research Institute of Rheumatology
Russian Federation

Irina G. Kirillova – Junior Researcher,  Rheumocardiology Laboratory.

Kashirskoe shosse 34a, Moscow, 115522.


H. V. Udachkina
V.A. Nasonova Research Institute of Rheumatology
Russian Federation

Helen V. Udachkina – Junior Researcher,  Rheumocardiology Laboratory.

Kashirskoe shosse 34a, Moscow, 115522.


T. V. Popkova
V.A. Nasonova Research Institute of Rheumatology
Russian Federation

Tatiana V. Popkova – MD, PhD, Leading Researcher,  Systemic Rheumatic Diseases Laboratory.

Kashirskoe shosse 34a, Moscow, 115522.



1. Nasonov E.L., Karateev D.E. Rheumatoid arthritis. In.: Nasonov E.L., ed. Russian clinical guidelines. Moscow: GEOTAR-Media; 2017. pp. 17-58. (In Rus.).

2. Dadoun S., Zeboulon-Ktorza N., Combescure C. et al. Mortality in rheumatoid arthritis over the last fifty years: systematic review and meta-analysis. Joint Bone Spine. 2013;80:29-33. doi:10.1016/j.jb-spin.2012.02.005.

3. Riise T., Jacobsen B.K., Gran J.T. et al. Total mortality is increased in rheumatoid arthritis. A 17-year prospective study. Clin Rheumatol. 2001;20:123-7.

4. Sokka T., Abelson B., Pincus T. Mortality in rheumatoid arthritis: 2008 update. Clin Exp Rheumatol.2008;26(5 Suppl 51):S35-61.

5. Agca R., Heslinga S.C., Rollefstad S. et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders:2015/2016 update. Ann Rheum Dis. 2017;76:17-28. doi:10.1136/annrheumdis-2016-209775.

6. Mareev V.Yu., Fomin I.V., Ageev F.T., et al. Clinical guidelines. Chronic heart failure (CHF). Heart Failure Journal. 2017;18(1):3-40/ (In Russ.). doi:10.18087/rhfj.2017.1.2346.

7. Ageev F.T., Danielyan M.O., Mareev V.Yu., et al. Patients with chronic heart failure in the Russian ambulatory practice: particular contingent, diagnosis and treatment (studies AGE-O-CHF). Heart Failure Journal. 2004;5(1):4-7. (In Russ.).

8. Wolfe F., Michaud K. Heart failure in rheumatoid arthritis: rates, predictors, and the effect of antitumor necrosis factor therapy. Am J Med. 2004;116:305-11. doi:10.1016/j.amjmed.2003.09.039

9. Gabriel S.E., Crowson C.S., O’Fallon W.M. Comorbidity in arthritis. J Rheumatol. 1999; 26:2475-9.

10. Nicola P.J., Maradit-Kremers H., Roger V.L. et al. The risk of congestive heart failure in rheumatoid arthritis: A population-based study over 46 years. Arthritis Rheum. 2005;52:412-20.

11. Pujades-Rodriguez M., Duyx B., Thomas S.L. et al. Rheumatoid arthritis and incidence of twelve initial presentations of cardiovascular disease: apopulation record-linkage cohort study in England. PLoS One 2016;15;11(3):e0151245. doi:10.1371/journal.pone.0151245.

12. Mantel A., Holmqvist M., Andersson D.C., et al. Association between rheumatoid arthritis and risk of ischemic and nonischemic heart failure J Am Coll Cardiol. 2017;69(10):1275-85. doi:10.1016/j.jacc.2016.12.033.

13. Norton S., Koduri G., Nikiphorou E., Dixey J. Study of baseline prevalence and cumulative incidence of comorbidity and extra-articular manifestations in RA and their impact on outcome. Rheumatology.2013;52:99-110. doi:10.1093/rheumatology/kes262

14. Wolfe F., Freundlich B., Straus W.L. Increase in cardiovascular and cerebrovascular disease prevalence in rheumatoid arthritis. J Rheumatol. 2003;30(1):36-40.

15. Crowson C.S., Nicola P.J., Kremers H.M., et al. How much of the increased incidence of heart failure in rheumatoid arthritis is attributable to traditional cardiovascular risk factors and ischemic heart disease? Arthritis Rheum. 2005;52:3039-44. doi:10.1002/art.21349.

16. Løgstrup BB, Ellingsen T. Development of heart failure in patients with rheumatoid arthritis: A Danish population-based study. Eur J Clin Invest. 2018;48(5):e12915. doi:10.1111/eci.12915.

17. Khalid U., Egeberg A., Ahlehoff O., et al. Incident heart failure in patients with rheumatoid arthritis: anationwide cohort study. J Am Heart Assoc. 2018;7(2). pii: e007227. doi:10.1161/JAHA.117.007227.

18. Pappas D.A., Nyberg F., Kremer J.M. et al. Prevalence of cardiovascular disease and major risk factors in patients with rheumatoid arthritis: a multinational cross-sectional study. Clin Rheumatol.2018;37(9):2331-40. doi:10.1007/s10067-018-4113-3.

19. Giles J., Fernandes V., Lima J.A., Bathon J.M. Myocardial dysfunction in rheumatoid arthritis: epidemiology and pathogenesis. Arthritis Res Ther. 2005;7(5):195-207. doi:10.1186/ar1814.

20. Ponikowski P., Voors A.A., Anker S.D., et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37:2129-200. doi:10.1093/eurheartj/ehw128.

21. Schau T., Gottwald M., ArbachO. et al. Increased prevalence of diastolic heart failure in patients with rheumatoid arthritis correlates with active disease, but not with treatment type J Rheumatol.2015;42(11):2029-37. doi:10.3899/jrheum.141647.

22. Davis III J.M., Roger V.L., Crowson C.S. et al. The presentation and outcome of heart failure in persons with rheumatoid arthritis differs from that of the general population. Arthritis Rheum.2008;58(9):2603-11. doi:10.1002/art.23798.

23. Vasan R.S., Larson M.G., Benjamin E.J., et al. Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: Prevalence and mortality in a population-based cohort. J Am Coll Cardiol. 1999;33:1948-55.

24. Nicola P.J., Crowson C.S., Maradit-Kremers H. et al. Contribution of congestive heart failure and ischemic heart disease to excess mortality in rheumatoid arthritis. Arthritis Rheum. 2006;54:60-7. doi:10.1002/art.21560.

25. Voskuyl A.E. The heart and cardiovascular manifestations in rheumatoid arthritis.Rheumatology (Oxford). 2006;45 Suppl 4:iv4-7. doi:10.1093/rheumatology/kel313.

26. Fonarow G.C., Horwich T.B. Prevention of heart failure: effective strategies to combat the growing epidemic. Rev Cardiovasc Med. 2003;4(1):8-17.

27. Paulus W.J., Tschope C., Sanderson J.E. et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J.2007;28:2539-50. doi:10.1093/eurheartj/ehm037.

28. Gavryushina SV, Ageev FT. Heart failure with preserved left ventricular ejection fraction: epidemiology, patient «portrait», clinic and diagnostics Kardiologiia. 2018;(S4):55-64. (In Russ.). doi:10.18087/cardio.2467.

29. Drapkina O.M., Kaburova A.N. Diastolic heart failure: pathophysiology and treatment perspectives. Heart Failure Journal. 2012; 13 (5):310-6. (In Russ.).

30. Castañeda S, González-Juanatey C, González-Gay MA. Sex and cardiovascular involvement in inflammatory joint diseases. Clinic Rev Allerg Immunol. doi:10.1007/s12016-017-8635-2 [Epub ahead of print].

31. Levy D., Larson M.G., Vasan R.S. et al. The progression from hypertension to congestive heart failure. J Am Med Assoc. 1996;275:1557-62.

32. Panoulas V.F., Douglas K.M., Milionis H.J., et al. Prevalence and associations of hypertension and its control in patients with rheumatoid arthritis. Rheumatology (Oxford). 2007;46:1477-82. doi:10.1093/rheumatology/kem169.

33. Novikova D.S., Popkova T.V., Nasonov E.L. Current knowledge about pathogenesis and treatment of arterial hypertension in rheumatoid arthritis. Ter Arkhiv. 2011;83(5):24-33. (In Russ.).

34. Diaconu C.C., Dediu G.N., Iancu M.A. Drug-induced arterial hypertension - a frequently ignored cause of secondary hypertension: a review. Acta Cardiol. 2018;1:1-7. doi:10.1080/00015385.2017.1421445.

35. Kannel W.B., Abbott R.D. Incidence and prognosis of unrecognized myocardial infarction. An update on the Framingham study. N Engl J Med. 1984;311:1144-7. doi:10.1056/NEJM198411013111802.

36. Elhendy A., Schinkel A.F.L, van Domburg R.T. et al. Incidence and predictors of heart failure during long-term follow-up after stress Tc-99m sestamibi tomography in patients with suspected coronary artery disease. J Nucl Cardiol. 2004;11:527-33. doi:10.1016/j.nuclcard.2004.04.011.

37. Solomon D.H., Karlson E.W., Rimm E.B. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation. 2003;107:1303-7.

38. Rincon I.D., Williams K., Stern M.P. et al. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum. 2001;44:2737-45.

39. Popkova T.V., Novikova D.S., Nasonov E.L. Cardiovascular diseases in rheumatoid arthritis: Latest data. Nauchno-Prakticheskaya Revmatologiya. 2016;54(2):122-8. (In Russ.). doi:10.14412/1995-4484-2016-122-128.

40. Gottdiener J.S., Arnold A.M., Aurigemma G.P. et al. Predictors of congestive heart failure in the elderly: the cardiovascular health study. J Am Coll Cardiol 2000;35:1628-37.

41. He J., Ogden L.G., Bazzano L.A. et al. Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study. Arch Intern Med. 2001;161:996-1002.

42. Ruscitti P., Ursini F., Cipriani P. et al. Prevalence of type 2 diabetes and impaired fasting glucose in patients affected by rheumatoid arthritis Results from a cross-sectional study. Medicine (Baltimore). 2017;96(34):e7896. doi:10.1097/MD.0000000000007896.

43. Mok C.C., Ko G.T., Ho L.Y., et al. Prevalence of atherosclerotic risk factors and the metabolic syndrome in patients with chronic inflammatory arthritis. Arthritis Care Res (Hoboken). 2011;63:195-202.

44. Baghdadi L.R., Woodman R.J., Shanahan E.M., Mangoni A.A. The impact of traditional cardiovascular risk factors on cardiovascular outcomes in patients with rheumatoid arthritis: a systematic review and meta-analysis. PLoS One. 2015;10(2):e0117952. doi:10.1371/journal.pone.0117952.

45. Lebowitz W.B. Heart in rheumatoid arthritis (rheumatoid disease): a clinical and pathological study of 62 cases. Ann Intern Med. 1963;58:102-23.

46. Guedes C., Bianchi-Fior P., Cormier B., et al. Cardiac manifestations of rheumatoid arthritis: A case-control transesophageal echocardiography study in 30 patients. Arthritis Rheum. 2001;45:129-35. doi:10.1002/1529-0131(200104)45:2<129::AID-ANR164>3.0.CO;2-K.

47. Corrao S., Messina S., Pistone G. et al. Heart involvement in rheumatoid arthritis: systematic review and meta-analysis. Int J Cardiol. 2013;167:2031-8. doi:10.1016/j.ijcard.2012.05.057.

48. Shingaki M., Kobayashi Y., Suzuki H. A case of acute aortic insufficiency due to severe rheumatoid arthritis, showing progression in two weeks. Cardiovasc Diagn Ther. 2014;4(3):267-9. doi:10.3978/j.issn.2223-3652.2014.06.07.

49. Hallowell R.W., Horton M.R. Interstitial lung disease in patients with rheumatoid arthritis: sponta- neous and drug induced. Drugs. 2014;74:443-450. doi:10.1007/s40265-014-0190-z.

50. Kim D., Cho S., Choi C., et al. Impact of interstitial lung disease on mortality of patients with rheuma- toid arthritis. Rheumatol Int. 2017;37(10):1735-145. doi:10.1007/s00296-017-3781-7.

51. Eaton C.B., Pettinger M., Rossouw J., et al. Risk factors for incident hospitalized heart failure with preserved versus reduced ejection fraction in a multiracial cohort of postmenopausal women. Circ Heart Fail. 2016;9:e002883. doi:10.1161/CIRCHEARTFAILURE.115.002883.

52. Kubota T., Miyagishima M., Alvarez R.J. et al. Expression of proinflammatory cytokines in the failing human heart: Comparison of recent-onset and endstage congestive heart failure. J Heart Lung Trans- plant. 2000;19:819-824.

53. Levine B., Kalman J., Mayer L. Elevated circulating levels of tumor-necrosis-factor in severe chronic heart failure. N Engl J Med. 1990;323:236-41. doi:10.1056/NEJM199007263230405.

54. Rauchhaus M., Doehner W., Francis D.P. et al. Cytokine parameters predict increased mortality in pa- tients with chronic heart failure. Circulation. 2000;102(25):3060-7.

55. Vasan R.S., Sullivan L.M., Roubenoff R. et al. Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: The Framingham heart study. Circulation. 2003;107:1486-91.

56. Cohn J.N., Ferrari R., Sharpe N. Cardiac remodeling - concepts and clinical implications: A consensus paper from an international forum on cardiac remodeling. J Am Coll Cardiol. 2000;35:569-82.

57. Kobayashi Y. Giles J.T., Hirano al. Assessment of myocardial abnormalities in RA using compre- hensive cardiac magnetic resonance approach: a pilot study. Arthritis Res Ther. 2010;12(5):R171. doi:10.1186/ar3131.

58. Recio-Mayoral A., Mason J.C., Kaski J.C., Rubens M.B., Harari O.A., Camici P.G. Chronic inflammation and coronary microvascular dysfunction in patients without risk factors for coronary artery disease. Eur Heart J. 2009;30(15):1837-43. doi:10.1093/eurheartj/ehp205.

59. Raza K, Banks M, Kitas GD. Reversing myocardial microvascular disease in a patient with rheumatoid arthritis. J Rheumatol. 2005;32(4):754-6.

60. Andersen J.K., Oma I., Prayson R.A., et al. Feiring Heart Biopsy Study Group. Inflammatory cell infiltrates in the heart of patients with coronary artery disease with and without inflammatory rheumatic disease: a biopsy study. Arthritis Res Ther. 2016;18(1):232. doi:10.1186/s13075-016-1136-5.

61. Ilter A., Kiris A., Karkucak M., et al. Arterial stiffness is associated with left ventricular dysfunction in patients with rheumatoid arthritis. Clin Rheumatol. 2016;35:2663-8. doi:10.1007/s10067-015-3163-z.

62. Myasoedova E., Crowson C.S., Nicola P.J. et al. The influence of rheumatoid arthritis disease charac- teristics on heart failure. J Rheumatol. 2011;38:1601-6. doi:10.3899/jrheum.100979.

63. Yurchak P.M., Deshpande V. A 60-year-old man with mild congestive heart failure of uncertain cause. N Engl J Med. 2003;348:243-9. doi:10.1056/NEJMcpc020025.

64. Felker G.M., Thompson R.E., Hare J.M. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med. 2000;342:1077-84. doi:10.1056/NEJM200004133421502.

65. Cathcart E.S., Spodick D.H. Rheumatoid heart disease. A study of the incidence and nature of cardiac lesions in rheumatoid arthritis. J Med. 1962;266:959-64. doi:10.1056/NEJM196205102661901.

66. Gonzalez-Juanatey C., Testa A., Garcia-Castelo A. et al. Echocardiographic and Doppler findings in long-term treated rheumatoid arthritis patients without clinically evident cardiovascular disease. Semin Arthritis Rheum. 2004;33:231-8.

67. Azzouz D., Sahli H., Hakim M. et al. Pericardial tamponade complicating rheumatoid arthritis: a case report. Rev Med Interne. 2008;29(4):331-4. doi:10.1016/j.revmed.2007.10.001.

68. Stolt P., Bengtsson C., Nordmark B. et al. Quantification of the influence of cigarette smoking on rheumatoid arthritis: results from a population based case-control study, using incident cases. Ann Rheum Dis. 2003;62:835-41.

69. Giles J.T., Fert-Bober J., Park J.K., et al. Myocardial citrullination in rheumatoid arthritis: a correlative histopathologic study. Arthritis Res Ther. 2012;14:R39. doi:10.1186/ar3752.

70. Fert-Bober J., Giles J.T., Holewinski R.J., et al. Citrullination of myofilament proteins in heart failure. Cardiovasc Res. 2015;108:232-42. doi:10.1093/cvr/cvv185.

71. Ungprasert P., Srivali N., Kittanamongkolchai W. et al. Risk of incident atrial fibrillation in patients with rheumatoid arthritis: a systematic review and meta-analysis. Int J Rheum Dis. 2017;20(4):434-41. doi:10.1111/1756-185X.12820.

72. Lazzerini P.E., Capecchi P.L., Laghi-Pasini F. Systemic inflammation and arrhythmic risk: lessons from rheumatoid arthritis. Eur Heart J. 2017;38(22):1717-27. doi:10.1093/eurheartj/ehw208.

73. Novikova D.S., Popkova T.V., Gerasimov A.N., et al. Silent myocardial ischemia and cardiac rhythm disturbances in women with rheumatoid arthritis. Clinician. 2013;7(3-4):31-9. (In Russ.). doi:10.17650/1818-8338-2013-3-4-31-39.


For citation:

Novikova D.S., Kirillova I.G., Udachkina H.V., Popkova T.V. Chronic Heart Failure in Rheumatoid Arthritis Patients (Part I): Prevalence, Etiology and Pathogenesis. Rational Pharmacotherapy in Cardiology. 2018;14(5):703-710. (In Russ.)

Views: 895

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)